Sathej Gopalakrishnan

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Andrew H. Wei, Pau Montesinos, Vladimir Ivanov et al. · Blood · 2020 · 725 citations · Full text

Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials

Xavier Montalbán, Patrick Vermersch, Douglas L. Arnold et al. · The Lancet Neurology · 2024 · 54 citations

Neurological Progress, Clinical Trials, Neurology +3

Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy

Deanna J. Brackman, Doerthe Eckert, Rajeev Menon et al. · Hematological Oncology · 2022 · 44 citations · Full text

Mixed-phenotype Acute Leukemia, Pharmacotherapy, Myeloid Neoplasia +16

Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure‐response analysis

Suresh Agarwal, Sathej Gopalakrishnan, Sven Mensing et al. · Hematological Oncology · 2019 · 41 citations

Upadacitinib pharmacokinetics and exposure‐response analyses of efficacy and safety in psoriatic arthritis patients – Analyses of phase III clinical trials

Elena Tomaselli Muensterman, Benjamin Engelhardt, Sathej Gopalakrishnan et al. · Clinical and Translational Science · 2021 · 36 citations · Full text